Skip to main content
SpringerLink
Log in

Gram-Positive Bacteria

  • Chapter
Management of Antimicrobials in Infectious Diseases

Part of the book series: Infectious Disease ((ID))

  • 214 Accesses

Abstract

The pneumococcus Streptococcus pneumoniae commonly grows in pairs (diplococci) but also can grow in short chains. An outer polysaccharide capsule protects the organism against phagocytosis, and pneumococcal virulence is related to the composition and size of the capsule (1). There are 90 known capsular types. Anticapsular antibodies induced by infection or vaccination are protective in normal hosts. The pneumococcal cell wall lies directly beneath the capsule and is composed of murein and glycopeptides. Cell wall antigens are responsible for the intense inflammatory reaction associated with pneumococcal infections. Cell wall components also facilitate pneumococcal attachment to and entry into activated host cells. The phosphorylcholine moiety of lipoteichoic acid structurally mimics platelet-activating factor (PAF). This allows pneumococci to subvert and attach to PAF receptors on cell surfaces (2). Pneumolysin is another important virulence factor produced by virtually all pneumococcal clinical isolates. A potent cytotoxin, pneumolysin injures neutrophils, endothelial cells, and alveolar epithelial cells (3).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Lee C, Banks SD, Li JP. Virulence, immunity and vaccine related to Streptococcus pneumoniae. Crit Rev Microbiol 1991; 18: 89–114.

    Article  PubMed  CAS  Google Scholar 

  2. Tuomanen EI, Austrian R, Masure HR. Pathogenesis of pneumococcal infection. N Engl J Med 1995; 332: 1280–1284.

    Article  PubMed  CAS  Google Scholar 

  3. Rubins JB, Janoff EN. Pneumolysin: a multifunctional pneumococcal virulence factor. J Lab Clin Med 1998; 131: 21–27.

    Article  PubMed  CAS  Google Scholar 

  4. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard. M100–S9. Ninth informational supplement to 4th edit. NCCLS document M7–A4, 1997; Wayne, PA: National Committee for Clinical Laboratory Standards, 1999.

    Google Scholar 

  5. Campbell GD Jr, Silberman R. Drug-resistant Streptococcus pneumoniae. Clin Infect Dis 1998; 26: 1188–1195.

    Article  PubMed  Google Scholar 

  6. Doern GV, Pfaller MA, Kugler D, Freeman J, Jones RN. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1977 results from the SENTRY antimicrobial surveillance program. Clin Infect Dis 1998; 27: 764–770.

    Article  PubMed  CAS  Google Scholar 

  7. Friedland IR, McCracken GH Jr. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 1994; 331: 377–382.

    Article  PubMed  CAS  Google Scholar 

  8. Kaplan SL, Mason EO. Management of infections due to antibiotic-resistant Streptococcus pneumoniae. Clin Microbiol Rev 1998; 11: 628–644.

    PubMed  CAS  Google Scholar 

  9. American Academy of Pediatrics. Dexamethasone therapy for bacterial meningitis. In Peter G (ed). Red Book: Report of the Committee on Infectious Diseases, 24th edit. Elk Grove Village, IL: American Academy of Pediatrics, 1977, pp. 620–2.

    Google Scholar 

  10. Quagliarello VJ, Scheld WM. Treatment of bacterial meningitis. N Engl J Med 1997; 336: 708–716.

    Article  PubMed  CAS  Google Scholar 

  11. Pallares R, Linares J, Vadillo M, Cabellos C, Manresa F, Viladrich PF. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 333: 474–480.

    Article  PubMed  CAS  Google Scholar 

  12. Bartlett JG, Brieman RF, Mandell LA, File TM. Community-acquired pneumonia in adults: guidelines for management. Clin Infect Dis 1998; 26: 811–838.

    Article  PubMed  CAS  Google Scholar 

  13. Silverstein M, Bachur R, Harper MB. Clinical implications of penicillin and ceftriaxone resistance among children with pneumococcal bacteremia. Pediatr Infect Dis J 1999; 18: 35–41.

    Article  PubMed  CAS  Google Scholar 

  14. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996; 15: 944–948.

    Article  Google Scholar 

  15. Barber M. Methicillin-resistant staphylococci. J Clin Pathol 1961; 14: 385–393.

    Article  PubMed  CAS  Google Scholar 

  16. Ayliffe GAJ. The progressive intercontinental spread of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 1997; 24 (Suppl 1): S74–79.

    Article  PubMed  Google Scholar 

  17. Harbarth S, Rutschmann O, Sudre P, Pittet D. Impact of methicillin resistance on the outcome of patients with bacteremia caused by Staphylococcus aureus. Arch Intern Med 1998; 158: 182–189.

    Article  PubMed  CAS  Google Scholar 

  18. Noble WC, Virani Z, Cree RGA. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992; 72: 195–198.

    Article  PubMed  CAS  Google Scholar 

  19. Sieradzki K, Tomasz A. A highly vancomycin-resistant laboratory mutant of Staphylococcus aureus. FEMS Microbiol Lett 1996; 142: 161–166.

    Article  PubMed  CAS  Google Scholar 

  20. Centers for Disease Control and Prevention. Reduced susceptibility of Staphylococcus aureus to vancomycin, Japan, 1996. MMWR 1997; 46: 624–626.

    Google Scholar 

  21. Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, Robinson-Dunn B, et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999; 340: 493–501.

    Article  PubMed  CAS  Google Scholar 

  22. Sieradzki K, Tomasz A. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J Bacteriol 1997; 179: 2557–2566.

    PubMed  CAS  Google Scholar 

  23. Sieradzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 1999; 340: 517–523.

    Article  PubMed  CAS  Google Scholar 

  24. Centers for Disease Control and Prevention. Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin. MMWR 1997; 46: 626–628, 635.

    Google Scholar 

  25. Martin RR, Buttram V, Besch P, Kirkland JJ, Pett GP. Nasal and vaginal Staphylococcus aureus in young women: quantitative studies. Ann Intern Med 1982; 96: 951–953.

    Article  PubMed  CAS  Google Scholar 

  26. Kain KC, Schulzer M, Chow A W. Clinical spectrum of nonmenstrual toxic shock syndrome (TSS): comparison with menstrual TSS by multivariate discriminant analyses. Clin Infect Dis 1993; 16: 100–106.

    Article  PubMed  CAS  Google Scholar 

  27. Nolan CM, Beaty HN. Staphylococcus aureus bacteremia: current clinical patterns. Am J Med 1976; 60: 495–500.

    Article  PubMed  CAS  Google Scholar 

  28. Raad II, Sabbagh MF. Optimal duration of therapy for catheter-related Staphylococcus aureus bacteremia: a study of 55 cases and review. Clin Infect Dis 1992; 14: 75–82.

    Article  PubMed  CAS  Google Scholar 

  29. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339:520–532.

    Google Scholar 

  30. Korzeniowski O, Sande MA, National Collaborative Study Group. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: a prospective study. Ann Intern Med 1982; 97: 496–503.

    Article  PubMed  Google Scholar 

  31. Byers KE, Durbin LJ, Simonton BM, et al. Disinfection of hospital rooms contaminated with vancomycin-resistant Enterococcus faecium. Infect Control Hosp Epidemiol 1998; 19: 261–264.

    Article  PubMed  CAS  Google Scholar 

  32. Smith TL, Iwen PC, Olson SB, et al. Environmental contamination with vancomycin-resistant enterococci in an outpatient setting. Infect Control Hosp Epidemiol 1998; 19: 515–518.

    Article  PubMed  CAS  Google Scholar 

  33. Morris JG Jr, Shay DK, Hebden JN, et al. Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a university medical center. Ann Intern Med 1995; 123: 250–259.

    Article  PubMed  CAS  Google Scholar 

  34. Shay DK, Maloney SA, Montecalvo M, et al. Epidemiology and mortality risk of vancomycinresistant enterococcal bloodstream infections. J Infect Dis 1995; 172: 993–1000.

    Article  PubMed  CAS  Google Scholar 

  35. Edmond MB, Ober JF, Weinbaum DL, et al. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis 1995; 20: 1126–1133.

    Article  PubMed  CAS  Google Scholar 

  36. Leclercq R, Courvalin P. Resistance to glycopeptides in enterococci. Clin Infect Dis 1997; 24: 545–556.

    Article  PubMed  CAS  Google Scholar 

  37. Edmond MB, Ober JF, Dawson JD, et al. Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis 1996; 23: 1234–1239.

    Article  PubMed  CAS  Google Scholar 

  38. Lucas GM, Lechtzin N, Puryear DW, et al. Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of clinical features and outcomes. Clin Infect Dis 1998; 26: 1127–1133.

    Article  PubMed  CAS  Google Scholar 

  39. Linden PK, Pasculle AW, Manez R, et al. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible Enterococcus faecium. Clin Infect Dis 1996; 22: 663–670.

    Article  PubMed  CAS  Google Scholar 

  40. Moellering RC Jr. Vancomycin-resistant enterococci. Clin Infect Dis 1998; 26: 1196–9.

    Article  PubMed  Google Scholar 

  41. Jones BL, Ludlam HA, Brown DF. High dose ampicillin for the treatment of high-level amino-glycoside resistant enterococcal endocarditis. J Antimicrob Chemother 94; 33: 891–892.

    Google Scholar 

  42. Papanicolaou GA, Meyers BR, Meyers J, et al. Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: risk factors for acquisition and mortality. Clin Infect Dis 1996; 23: 760–766.

    Article  PubMed  CAS  Google Scholar 

  43. Lautenbach E, Schuster MG, Bilker WB, et al. The role of chloramphenicol in the treatment of bloodstream infections due to vancomycin-resistant Enterococcus. Clin Infect Dis 1998; 27: 1259–1265.

    Article  PubMed  CAS  Google Scholar 

  44. Whitman MS, Pitsakis PG, Zausner A, et al. Antibiotic treatment of experimental endocarditis due to vancomycin-and ampicillin-resistant Enterococcus faecium. Antimicrob Agents Chemother 1993; 37: 2069–2073.

    Article  PubMed  CAS  Google Scholar 

  45. Perri MB, Chow JW, Zervos MJ. In vitro activity of sparfloxacin and clinafloxacin against multidrug-resistant enterococci. Diagn Microbiol Infect Dis 1993; 17: 151–155.

    Article  PubMed  CAS  Google Scholar 

  46. Feldman RJ, Paul SM, Silber JL, et al. An analysis of treatment of patients with vancomycinresistant enterococcal bacteremia. Infect Dis Clin Pract 1996; 5: 440–445.

    Article  Google Scholar 

  47. Chant C, Rybak MJ. Quinupristin/dalfopristin (RP 59500): a new streptogramin antibiotic. Ann Pharmacother 1995; 29: 1022–1027.

    PubMed  CAS  Google Scholar 

  48. Goto S, Miyazaki S, Kaneko Y. The in vitro activity of RP 59500 against Gram-positive cocci. J Antimicrob Chemother 1992; 30: S25–28.

    Article  Google Scholar 

  49. Fuller RE, Drew RH, Perfect JR. Treatment of vancomycin-resistant enterococci with a focus on quinupristin-dalfopristin. Pharmacotherapy 1996; 16: 584–592.

    PubMed  CAS  Google Scholar 

  50. Lin AH, Murray RW, Vidmar TJ, et al. The oxazolidinone eperezolid binds to the 50S ribosome subunit and competes with binding of chiorampheicol and lincomycin. Antimicrob Agents Chemother 1997; 41: 2127–2131.

    PubMed  CAS  Google Scholar 

  51. Demyan WF, Swaney SM, Shinabarger DL. The oxazolidinone linezolid inhibits translation initiation in bacteria. In: Program and Abstracts, 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 28-October 1, 1997, Toronto, Canada. Abstract C102.

    Google Scholar 

  52. Zurenko GE, Yagi BH, Schaadt RD, et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996; 40: 839–845.

    PubMed  CAS  Google Scholar 

  53. The Hospital Infection Control Practices Advisory Committee, Centers for Disease Control and Prevention, Atlanta, GA. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Conmiittee (HICPAC). Am J Infect Control 1995; 23: 87–94.

    Article  Google Scholar 

  54. Jochimsen EM, Fish L, Manning K, et al. Control of vancomycin-resistant enterococci at a community hospital: efficacy of patient and staff cohorting. Infect Control Hosp Epidemiol 1999; 20: 106–109.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Thomas S. Stalder
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laurel C. Preheim
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medical University of South Carolina, Charleston, SC, USA

    Arch G. Mainous III PhD

  2. College of Medicine, University of Kentucky, Lexington, KY, USA

    Claire Pomeroy MD

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Science+Business Media New York

About this chapter

Cite this chapter

Stalder, T.S., Preheim, L.C. (2001). Gram-Positive Bacteria. In: Mainous, A.G., Pomeroy, C. (eds) Management of Antimicrobials in Infectious Diseases. Infectious Disease. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-036-0_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-036-0_2

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-5708-8

  • Online ISBN: 978-1-59259-036-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation